September 2018 ASBMT Monthly Self-Directed Learning Quiz

On behalf of the ASBMT Committee on Education, we are pleased to continue our monthly self-directed learning quiz "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy – Question and Answer Approach” for fellows in training, highlighting HCT and cell therapy topics. Answers to each question appear with evidence-based “non-exhaustive” peer-review commentary. Our aim is to provide you with a credible and freely available educational resource. Questions generated and reviewed by Syed Abutalib, MD, Mark R. Litzow, MD, and William A. Wood, MD.

Question Title

* 1. Which of the following statements about mechanism of action of granulocyte colony-stimulating factor (G-CSF) is CORRECT?

A. G-CSF upregulates CXCL12 synthesis

B. G-CSF deactivates proteases in bone marrow

C. G-CSF upregulates SDF-1 expression

D. G-CSF might be involved in cleavage of CXCR4

Question Title

* 2. AETHERA trial⁵ aimed to assess whether brentuximab vedotin improves progression free survival when given as early consolidation after autologous hematopoietic cell transplantation in subjects (age ≥18 years) with high-risk relapsed and primary refractory classic Hodgkin's lymphoma.

Which of the following statements is CORRECT?

A. It was a multicenter single-arm prospective trial

B. Brentuximab vedotin improved progression free survival

C. The trial was terminated early due to poor accrual

D. Brentuximab vedotin was administered at a dose of 1.2 mg/kg every 3 weeks for 2 years

Question Title

* 3. Which statement about autologous transplant and post-transplant consolidation therapy in classic Hodgkin’s lymphoma is CORRECT?

A. Autologous hematopoietic cell transplantation is the standard of care for patients in whom frontline therapy has been ineffective and who are regarded as transplant eligible on the basis of disease status and ability to tolerate the treatment

B. Roughly 30% of patients might be cured with autologous transplantation in relapsed or refractory settings

C. Consolidation therapy with brentuximab vedotin is the standard of care approach for all patients after autologous transplantation

D. A and C

Question Title

* 4. Which of the following reflects distinct long-term hematopoietic stem cell phenotypic signature (flow cytometry-based characterization)

A. Lin-, CD34-, CD38-

B. Lin+, CD34+, CD38+

C. Lin-, CD34+, CD38-

D. Lin+, CD34+, CD38-

Question Title

* 5. Which statement about overall utilization of unrelated donors in pediatric allogeneic transplants is CORRECT?

A. Bone marrow remains the most common graft source

B. Use of umbilical cord blood peaked in 2009

C. Peripheral blood accounted for 21% of pediatric unrelated donor graft type in 2016.

D. All of the above